The estimated Net Worth of James B Breitmeyer is at least $1.93 millió dollars as of 13 April 2023. James Breitmeyer owns over 150,000 units of Oncternal Therapeutics stock worth over $816,640 and over the last 11 years he sold ONCT stock worth over $0. In addition, he makes $1,115,840 as President, Chief Executive Officer és Director at Oncternal Therapeutics.
Sign up
James Breitmeyer ONCT stock SEC Form 4 insiders trading
James has made over 4 trades of the Oncternal Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 150,000 units of ONCT stock worth $43,500 on 13 April 2023.
The largest trade he's ever made was buying 150,000 units of Oncternal Therapeutics stock on 13 April 2023 worth over $43,500. On average, James trades about 5,000 units every 33 days since 2014. As of 13 April 2023 he still owns at least 196,544 units of Oncternal Therapeutics stock.
You can see the complete history of James Breitmeyer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Breitmeyer biography
Dr. James B. Breitmeyer M.D. Ph.D. serves as President, Chief Executive Officer, Director of the Company. Breitmeyer served as a member of the board of directors of Private Oncternal and as President and Chief Executive Officer of Private Oncternal since September 2015. Dr. Breitmeyer is a veteran biotech executive with experience successfully starting and growing biotechnology organizations. He has been responsible for both the development and implementation of both operational and drug development strategies, as well as supervising and managing both large organizations and emerging biotechnology companies. Dr. Breitmeyer served as President of Bavarian Nordic, Inc. and Executive Vice President of Bavarian Nordic A/S, a multinational corporation headquartered in Denmark, from February 2013 to July 2015 where he oversaw business operations and development strategy both for Bavarian Nordic, Inc. and Bavarian Nordic A/S. He has been a director of Zogenix, Inc., a public pharmaceutical company, since March 2014, and was their acting Chief Medical Officer from August 2012 to February 2013 where he was responsible for clinical development and regulatory strategy. He previously served as the Executive Vice President of Development and Chief Medical Officer of Cadence Pharmaceuticals Inc., a public pharmaceutical company, from August 2006 to August 2012, and the Chief Medical Officer of Applied Molecular Evolution Inc., a wholly-owned subsidiary of Eli Lilly and Co., a global pharmaceutical company, from December 2001 to August 2006. Dr. Breitmeyer was also the founder, President and Chief Executive Officer of the Harvard Clinical Research Institute, and Chief Medical Officer and Head of Research & Development for North America at Serono Laboratories Inc., an international biopharmaceutical company. Dr. Breitmeyer served as a founding collaborator and scientific advisor to Immunogen Inc., a biotechnology company, and held clinical and teaching positions at the Dana Farber Cancer Institute and Harvard Medical School.
What is the salary of James Breitmeyer?
As the President, Chief Executive Officer és Director of Oncternal Therapeutics, the total compensation of James Breitmeyer at Oncternal Therapeutics is $1,115,840. There are no executives at Oncternal Therapeutics getting paid more.
How old is James Breitmeyer?
James Breitmeyer is 66, he's been the President, Chief Executive Officer és Director of Oncternal Therapeutics since 2019. There are 5 older and 9 younger executives at Oncternal Therapeutics. The oldest executive at Oncternal Therapeutics, Inc. is Michael Carter, 82, who is the Independent Director.
What's James Breitmeyer's mailing address?
James's mailing address filed with the SEC is 12230 EL CAMINO REAL, SUITE 230, , SAN DIEGO, CA, 92130.
Insiders trading at Oncternal Therapeutics
Over the last 5 years, insiders at Oncternal Therapeutics have traded over $26,287 worth of Oncternal Therapeutics stock and bought 1,526,610 units worth $3,062,129 . The most active insiders traders include Pharmaceutical (Usa) Inc.Sh..., Charles Theuer és Robert James Wills. On average, Oncternal Therapeutics executives and independent directors trade stock every 68 days with the average trade being worth of $302,970. The most recent stock trade was executed by Robert James Wills on 8 April 2024, trading 3,086 units of ONCT stock currently worth $27,651.
What does Oncternal Therapeutics do?
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. The company also develops a chimeric antigen receptor T cell therapy that targets Receptor tyrosine kinase-like Orphan Receptor 1, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors. In addition, it is developing TK216, an investigational small molecule that inhibits the E26 Transformation Specific family of oncoproteins. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; Shanghai Pharmaceutical (USA) Inc.; Selexis S.A.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting receptor-tyrosine kinase-like Orphan Receptor 1. The company is headquartered in San Diego, California.
What does Oncternal Therapeutics's logo look like?
Complete history of James Breitmeyer stock trades at Otonomy Inc, Zogenix Inc és Oncternal Therapeutics
Oncternal Therapeutics executives and stock owners
Oncternal Therapeutics executives and other stock owners filed with the SEC include:
-
James Breitmeyer,
President, Chief Executive Officer, Director -
Dr. James B. Breitmeyer,
Pres, CEO & Director -
Frank Hsu,
Chief Medical Officer -
Dr. Gunnar F. Kaufmann Ph.D.,
Chief Scientific Officer -
Charles Theuer,
Independent Director -
William LaRue,
Independent Director -
Daniel Kisner,
Independent Director -
Michael Carter,
Independent Director -
Nakanishi Xin,
Director -
Robert Wills,
Director -
Man Cho,
Director -
Igor Bilinsky,
Chief Business Officer -
Gunnar Kaufmann,
Chief Scientific Officer -
Richard Vincent,
Chief Financial Officer, Treasurer, Secretary -
David Hale,
Independent Chairman of the board -
Dr. Steven Hamburger Ph.D.,
Sr. VP of Regulatory Affairs & Quality Assurance -
Dr. Salim Yazji,
Chief Medical Officer -
Pablo Urbaneja,
Sr. VP of Corp. Devel. -
Chase C. Leavitt,
Gen. Counsel -
Dr. Rajesh Krishnan Ph.D.,
Chief Technology Officer -
Rajesh Krishnan,
CTO/CSO -
Pharmaceutical (Usa) Inc.Sh...,
-
Yanjun Liu,
Director -
Hazel M Aker,
Legal Counsel -
Pharmaceutical (Usa) Inc. S...,
10% owner -
Rosemary Mazanet,
-
Jinzhu Ph D Chen,
Director -
Chase C. Leavitt,
General Counsel/Secretary -
Salim Yazji,
Chief Medical Officer -
Jill De Simone,